Background: The genetic background plays an important role in thrombosis and pregnancy morbidities. Low levels of protein Z is associated with increased risk of thrombosis. The G79A polymorphism in the protein Z gene may be a genetic risk factor for thrombosis. Aim of the study: To investigate the prevalence and clinical significance of the protein Z-79 G/ A gene polymorphism in Egyptian patients with antiphospholipid syndrome (APS). Methods: We genotyped 60 APS patients and 41 controls, for protein Z-79 G/A gene polymorphism using the PCR-restriction fragment length. The polymorphism was then analyzed in relation to thrombosis and pregnancy morbidities in APS patients. Results: We observed a higher prevalence of the A allele in the controls when compared to the APS patients (P Value = <0.001). In our studied sample, the G79A polymorphism, as well as its minor A allele, were not associated with an increased risk of thrombosis or pregnancy morbidities in APS.
Introduction
Antiphospholipid syndrome (APS) is a crucial thrombophilic condition which is characterized mainly by vascular thrombosis (venous, arterial or microvascular) associated with imaging, or histologic evidence of thrombosis in any tissue or organ and/or an adverse pregnancy outcome attributable to placental insufficiency in patients. This, simultaneously with laboratory evidence of antibodies directed against proteins that bind to phospholipids (antiphospholipid antibodies (aPL)), for 12 weeks. Diagnosis of APS requires both clinical evidence of thrombosis and laboratory evidence of aPL antibodies [1] . APS is either primary autoimmune disease or secondary to underlying disease, such as systemic lupus erythematosus (SLE).
Blood coagulation is tightly controlled by members of the serine protease inhibitors; one of which is activated factor X (FXa), which is the key enzyme in prothrombin activation [2] . Protein Z (PZ)-dependent inhibitor (ZPI), tissue factor pathway inhibitor (TFPI) and antithrombin play the main role in regulating the function of factor X. However, ZPI is relatively inactive in the absence of its cofactor, PZ [3, 4] .
ZPI inhibits FXa that is found on platelets and other membranes through its binding to PZ [5] . Deficiency of ZPI or PZ has been associated with venous thrombosis and peripheral arterial disease [6, 7] . Protein Z deficiency is also said to contribute to pregnancy morbidities such as, early fetal death, intrauterine growth restriction [8] , and recurrent spontaneous abortion [9] .
The ZPI/PZ inhibitors system play a crucial role in pathogenesis of APS, an impairment in the ZPI / PZ inhibitor system has been reported in APS patients [10] .
The expression of Protein Z is affected by protein Z-79 G/A gene polymorphism. It was noted that carriers of the 79 AA genotypes may have lower PZ concentrations in plasma [11] .
In our study we investigate the prevalence and clinical significance of the protein Z-79 G/A gene polymorphism in Egyptian patients with APS.
Materials and methods

Clinical demography
In our study, sixty APS patients and forty-one age and gender matched, healthy volunteer were enrolled. The APS patients enrolled in this study was recruited from hematology outpatient clinics or Hematology, Rheumatology or High Risk Pregnancy Wards of Kasr Alainy Hospital, between April 2015 and September 2016.The study protocol was approved by the hospital ethical committee.
APS patients were diagnosed according to the Sydney criteria [1] . The patients with active cancer, receiving chemotherapy or with impaired liver functions were excluded. The controls had no history or clinical evidence of previous thrombosis or pregnancy morbidities. All individuals enrolled in this study, were more than 18 years old and they signed an informed consent before enrollment.
The patients filled in a questionnaire including thorough questions regarding previous arterial thrombotic events, venous thrombotic events and pregnancy morbidities. The data obtained from each patient about the risk factors of thrombosis included: immobility, recent surgery, catheterization induced vascular injury, smoking, diabetes, heavy proteinuria, peripartum period, hormonal therapy and family history of thrombosis.
Measurements of serum titres of lupus anticoagulant (LA), anticardiolipin (aCL) antibodies (IgG and IgM isotypes) and/ or B2 glycoprotein antibodies (IgG and IgM isotypes), as well as 24 hours urinary protein, was performed for all the patients engaged in our study who were diagnosed with APS.
In our study, LA was tested using diluted Russell viper venom time (dRVVT) for screening and mixing study [12] . Mixing study is formulated as the ratio of dRVVT of 1:1 mixing of patient and normal pooled plasma, divided by dRVVT of normal plasma. The anticardiolipin (aCL) and ab2GPI antibodies were measured using enzyme-linked immunosorbent assay (ELISA) method, as in the proposals of the Standardization Group of the European Forum on antiphospholipids antibodies [13, 14] . For both aCL Ab and ab2GPI antibodies, we considered high positive titer if the level were 40 units/ml, and low positive titer if levels were positive but <40 units/ml [1] .
The detection of protein Z (rs3024735) polymorphism, Intron F G79A; was determined by the PCR-restriction fragment length polymorphism technique (PCR-RFLP). This was applied to the samples obtained from the101 individuals enrolled in our study.
Molecular analysis
DNA was extracted from the enrolled subjects in this study using a Qiagen extraction kit (catalog number 51104, USA). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used to detect the genotypes of protein Z gene (rs17882561) SNP.
The target gene was amplified by PCR using 5 0 -TAACACCA TAGACAGAGTCCGATATTCGC-3 0 (sense) and 5 0 -ATGAACTCG GCATTAGAACATGGTTGGA-3 0 (antisense) primers (spanning PZ intron F region containing rs17882561 site).
A PCR assay was performed on each sample in a final reaction volume of 25 µL, using 5 µL genomic DNA, 12.5 µL universal master mix (0.1 units/lLTaq DNA Polymerase, 32 mM (NH 4 ) 2 SO 4 , 130 mM Tris HCl, 5.5 mM MgCl 2 , and 0.4 mM of each dNTP), 1 µL forward primer, 1 µL reverse primer, together with 5.5 µL distilled water (DW). The PCR conditions were as follows: an initial heat activation step at 94°C for 4 minutes followed by 32 cycles with the following program: denaturation at 94°C for 60 seconds, annealing at 57°C for 60 seconds, and finally extension at 74°C for 60 seconds. After amplification, The PCR product was digested with 10 U HpaI enzyme (Fermentas Life Sciences, USA) in the manufacturer's buffer at 37°C overnight. The products were then resolved on 2% agarose gel electrophoresis gels containing ethidium bromide, and then visualized using a UV transilluminator. DNA molecular weight marker (QIAGEN GelPilot 50 bp Ladder) {cat no. 239 025} was used to assess the size of the PCR-RFLP products. The amplified fragment (320 bp), after digestion with HpaI restriction enzyme, can give rise to either 3 fragments at 320, 221, and 99 bp which indicates the presence of the heterozygous type (GA), or 2 fragments at 221 and 99 bp which indicates the presence of the homozygous minor type (AA) or remains undigested as 1 fragment at 320 bp for the wild genotype (GG) (Fig. 1) .
Statistical Methods
The statistical package SPSS version 23 was used for data entry. The data was expressed as mean and standard deviation for quantitative variables and frequencies (number of cases), and relative frequencies (percentages) for categorical variables. Comparisons between quantitative variables were done using unpaired T test. Chi square (v2) test was used for comparing categorical data. Exact test was used instead when the expected frequency was less than 5. Chisquare test was used for comparing genotype and allele frequencies between the patients and the volunteer groups. The odds ratio (OR) with 95% confidence intervals was calculated. P-values <0.05 were considered as statistically significant.
Results
In our study six (10%) patients were males while 54 (90%) were females, the mean age of the 60 cases was 31.03 years. Twenty seven (45%) patients were diagnosed as primary APS, while 33 (55%) were diagnosed as secondary APS.
The number of thrombotic events and pregnancy morbidities is summarized in Table 1 .Out of the 60 APS patients, 31 patients (51.7%) had no DVTs, 18 patients (30%) had one DVT, 5 patients (8.3%) had two DVTs and six patients (9%) had three or more DVTs.
The frequency of the different thrombotic risk factors in APS patients in the form of Diabetes, hypertension, smoking, proteinuria, immobility, recent surgery and intake of hormone replacement therapy is summarized in Table 2 . Out of the 61 patients, 23 patients (38.3%) had no risk factors, 26 patients (43.3%) had one and 11 patients (18.3%) had two to three risk factors.
The distribution of protein Z-79 G/A gene polymorphism among the study group shows that 48 patients (80%) carry the wild type genotype (GG), while only 12 patients (20%) carry the mutant heterozygous genotype (GA). Among the control group, 23 controls (56.1%) carry the mutant heterozygous genotype (GA), while 18 controls (43.9%) carry the wild type genotype (GG). Neither a patient, nor a control carries the homozygous mutant genotype (AA).
The distribution of protein Z genotype among the patients and controls, showed a statistical significant difference (P value = <0.001), with the mutant genotype being higher in the controls than in the patients. The incidence of the A Allele was significantly higher in the control group (n = 23 [28%]) when compared to the APS group (n = 12, [10%]) (P value = <0.01, Odd ratio = 0.196) (Table 3) .
However, the distribution of protein Z-79 G/A gene polymorphism in relation to the various thrombotic events (venous or arterial) and pregnancy co-morbidities in our APS patients seemed to show no statistically significant difference (Table 4) .
In addition, when we compared the distribution of protein Z-79 G/A gene polymorphism and the incidence of The relation between protein Z polymorphism and the risk of thrombosis in Egyptian patientsrecurrence of DVTs and number of abortions, no statistical significance was found (Table 5 ).
There is also no statistically significant difference was found between the various risk factors for thrombosis and the distribution of protein Z (rs3024735) polymorphism, in the studied group of APS patients (Table 6 ).
Discussion
APS is a common hypercoaguable state characterized by venous/arterial thrombosis and/or pregnancy morbidities.
PZ is acts as a cofactor for the ZPI, which in turn inhibits FXa and FXIa, subsequently reducing thrombin generation and inhibiting coagulation. Protein Z levels may be affected by polymorphisms in the protein Z gene and so this polymorphism may play a role in thrombosis.
We studied the distribution of the protein Z gene (rs3024735) (G79A) single-nucleotide polymorphism by PCR-RFLP, in 60 APS patients and 41 healthy volunteer, aiming at detecting the prevalence and clinical significance of protein Z gene G79A polymorphism among Egyptian APS patients. As far as our knowledge goes, this is the first study to be conducted concerning the relation between this gene polymorphism and its prevalence and clinical significance in APS patients. However, similar studies were carried on the protein Z G79A gene polymorphism in association to other diseases (e.g. SLE and sickle cell disease) or in association to certain types of thrombosis or pregnancy co-morbidities in general (11, 12) .
Our study showed that there was a statistically significant difference in the distribution of the genotypes of protein Z G79A polymorphism between APS patients and the control group with a p value <0.001. The heterozygous genotype (GA) was found to be significantly higher in the controls when compared to the cases. A statistically significant difference in the frequency of the alleles, was also detected with a higher prevalence of the A allele in the controls when compared to the APS patients, with a P value <0.001, suggesting that there may be a protective role for the genetic polymorphism.
Similarly, an Egyptian study conducted on 40 women with recurrent miscarriage (not necessarily diagnosed as APS) and 30 control women has reported a significant higher prevalence of the 79A allele in controls when compared to cases (P = 0.008) [15] . In concordance with our findings, an Austrian study carried on 49 cases with recurrent miscarriages (not necessarily APS patients) and 48 controls also reported that the 79A allele, individually and in combination with other thrombophilic risk factors (factor V Leiden and increased factor VIII activity), was associated with a reduced risk of early (8-12 weeks of gestation) spontaneous fetal loss [16] .
Three studies showed that the incidence of the A allele (G79A polymorphism) in the control group was higher than in the patients who had a stroke, which suggests that the A allele of this polymorphism might 'protect' against strokes in young age [17, 18, 7] .
Contradictory to our findings though, were the findings stated by Yousry et al, in a study carried on 100 SLE patients Table 3 The frequency distribution of (rs3024735) protein Z polymorphism and different alleles in patients and controls groups.
Protein ''Z" Polymorphism (rs3024735)
Cases ( and 100 matched controls, revealed statistically insignificant difference in the distribution of the genotypes between SLE patients and the control group. However, there was a statistically significant difference in the frequency of the alleles distribution between SLE patients and controls (P = 0.024). The study also reported a statistically significant association between the minor A allele and the occurrence of thrombosis [19] . Our study however, showed that there is no statistically significant association between the G79A protein Z genotypes (and also the A allele) and the incidence of thrombosis (arterial or venous).
The association between protein Z G79A polymorphism and risk of thrombosis is controversial; in agreement with our study, Lichy et al's study, conducted in 2006 concluded that cerebral venous thrombosis did not affected by G79A gene polymorphism [20] . However, a retrospective genetic study comparing 100 healthy controls to 54 patients revealed that patients with cerebral venous thrombosis more often had polymorphic variants of the G79A polymorphism when compared with the control group [21] .
Furthermore, a large Bahraini study conducted on 287 women with idiopathic miscarriage and 308 control women, showed that the G79A minor allele was associated with an increased risk of adverse pregnancy outcomes. [9] .On the contrary, Topalidou et al., showed no statistical significant difference in the distribution of the A allele between the cases with idiopathic fetal loss and the controls [22] .
This controversy can be explained by the different genetic background of each population.
Conclusions
Protein Z G79A polymorphism seems to be of a protective value against APS as it was observed to be higher in healthy controls when compared to patients with APS. In light of the previous conclusion, we can say that the distribution of this Protein Z polymorphism could not be considered an independent risk factor for thrombosis in APS patients.
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